Figure 7. IRF3 is required for polyI∶C-driven antiviral protection in Ad/Tr-cells.

(A) HEC-1A cells were left untreated or transfected with a non-targeting control siRNA (ctrl siRNA), or IRF3 siRNA (IRF3 siRNA) for 48 h. Two days after siRNA delivery, HEC-1A received MOI 50 of Ad/dl or Ad/Tr followed by 25 µg/ml of polyI∶C treatment for 24 h and Western blot analyses of total IRF3 (tIRF3) and GAPDH proteins were performed from whole-cell extracts 96 h post-transfection. (B) Twenty four hours following polyI∶C treatment, cells were infected with MOI 1 of VSV-GFP for another 24 h. Levels of GFP fluorescence were visualized and quantified using a Typhoon scanner. The fluorescence reading of treated cultures was normalized to untreated (control) cultures and presented as percentage relative fluorescence. The data are representative of two independent experiments performed in triplicate and are shown as the mean ± SD. Statistical analysis was performed using Student's t test with * representing significant difference between the groups, p<0.05.